Supplements

A supplement to Ob.Gyn. News. This supplement was sponsored by Ethicon Women's Health & Urology.

•Topics
•Faculty/Faculty Disclosure

To view the supplement, click the image above.

• Introduction
• Total Versus Subtotal Abdominal Hysterectomy
• A Retrospective Comparison of LSH and TAH
• Two Approaches to Hysterectomy for Management of Benign Pathology

Faculty/Faculty Disclosure

Andrew I. Brill, MD
Director of Minimally Invasive Gynecology at California Pacific Medical Center
San Francisco, CA
Dr. Brill has a consulting agreement with Cephalon, Inc., Ethicon, Inc., and Karl Storz GmbH & Co. KG.

Copyright © 2010 by Elsevier Inc.

A supplement to Ob.Gyn. News. This supplement was sponsored by Ethicon Women's Health & Urology.

•Topics
•Faculty/Faculty Disclosure

To view the supplement, click the image above.

• Introduction
• Total Versus Subtotal Abdominal Hysterectomy
• A Retrospective Comparison of LSH and TAH
• Two Approaches to Hysterectomy for Management of Benign Pathology

Faculty/Faculty Disclosure

Andrew I. Brill, MD
Director of Minimally Invasive Gynecology at California Pacific Medical Center
San Francisco, CA
Dr. Brill has a consulting agreement with Cephalon, Inc., Ethicon, Inc., and Karl Storz GmbH & Co. KG.

Copyright © 2010 by Elsevier Inc.

A supplement to Ob.Gyn. News. This supplement was sponsored by Ethicon Women's Health & Urology.

•Topics
•Faculty/Faculty Disclosure

To view the supplement, click the image above.

• Introduction
• Total Versus Subtotal Abdominal Hysterectomy
• A Retrospective Comparison of LSH and TAH
• Two Approaches to Hysterectomy for Management of Benign Pathology

Faculty/Faculty Disclosure

Andrew I. Brill, MD
Director of Minimally Invasive Gynecology at California Pacific Medical Center
San Francisco, CA
Dr. Brill has a consulting agreement with Cephalon, Inc., Ethicon, Inc., and Karl Storz GmbH & Co. KG.

Copyright © 2010 by Elsevier Inc.

A supplement to Ob.Gyn. News. This supplement was sponsored by TEVA Women's Health.

•Topics
•Faculty/Faculty Disclosure

To view the supplement, click the image above.

• History of the Hormone-Free Interval
• Physiologic Effects of a Modified Hormone-Free Interval
• Safety and Efficacy of Extended-Regimen Oral Contraception

Faculty/Faculty Disclosure

David J. Portman, MD
Director and Principal Investigator
Columbus Center for Women's
Health Research
Columbus, Ohio
Dr. Portman is a consultant to Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, and TEVA Women's Health. He has received funding for clinical grants from Bayer, Boehringer Ingelheim, Depomed, Inc., Pfizer Inc., TEVA Women's Health, and Warner Chilcott.

A supplement to Ob.Gyn. News. This supplement was sponsored by TEVA Women's Health.

•Topics
•Faculty/Faculty Disclosure

To view the supplement, click the image above.

• History of the Hormone-Free Interval
• Physiologic Effects of a Modified Hormone-Free Interval
• Safety and Efficacy of Extended-Regimen Oral Contraception

Faculty/Faculty Disclosure

David J. Portman, MD
Director and Principal Investigator
Columbus Center for Women's
Health Research
Columbus, Ohio
Dr. Portman is a consultant to Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, and TEVA Women's Health. He has received funding for clinical grants from Bayer, Boehringer Ingelheim, Depomed, Inc., Pfizer Inc., TEVA Women's Health, and Warner Chilcott.

A supplement to Ob.Gyn. News. This supplement was sponsored by TEVA Women's Health.

•Topics
•Faculty/Faculty Disclosure

To view the supplement, click the image above.

• History of the Hormone-Free Interval
• Physiologic Effects of a Modified Hormone-Free Interval
• Safety and Efficacy of Extended-Regimen Oral Contraception

Faculty/Faculty Disclosure

David J. Portman, MD
Director and Principal Investigator
Columbus Center for Women's
Health Research
Columbus, Ohio
Dr. Portman is a consultant to Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, and TEVA Women's Health. He has received funding for clinical grants from Bayer, Boehringer Ingelheim, Depomed, Inc., Pfizer Inc., TEVA Women's Health, and Warner Chilcott.

A supplement to Ob.Gyn. News.
This supplement is based on physician interviews. It is supported by Kenwood Therapeutics, a division of Bradley Pharmaceuticals, Inc.

To view the supplement, click the image above.

Topic Highlights

• Menopause and Hormone Therapy

• The Cardiovascular Paradox

• Current Recommendations for Postmenopausal Hormone Therapy

• Effective Low-Dose Therapy

• Clinical Trial of Transdermal Estrogen

• Other Considerations of Transdermal Hormone Therapy

Faculty/Faculty Disclosures

Donna Shoupe, MD
Professor, Department of Obstetrics and Gynecology
Keck School of Medicine
University of Southern California
Dr. Shoupe is on the advisory board of Bradley Pharmaceuticals, Inc.
Steven R. Goldstein, MD
Professor of Obstetrics and Gynecology
New York University School of Medicine
Dr. Goldstein has disclosed that he is on the advisory boards of Bradley Pharmaceuticals, Inc., Eli Lilly and Company, GlaxoSmithKline, Merck & Co., Inc., Novogyne Pharmaceuticals, Novo Nordisk, and Pfizer Inc.

With Comments From:
Daniel R. Mishell, Jr., MD
Lyle G. McNiele Professor
Department of Obstetrics/Gynecology
Keck School of Medicine
University of Southern California
Dr. Mishell has disclosed that he is a consultant to Barr Pharmaceuticals, Inc., and Bayer Healthcare Pharmaceuticals Inc.
Alfred Moffett Jr., MD, FACOG
Clinical Assistant Professor, Obstetrics and Gynecology
University of South Florida College of Medicine
OB-GYN Associates of Mid-Florida, P.A.
Dr. Moffett is on the advisory board of Bradley Pharmaceuticals, Inc.
Lee P. Shulman, MD, FACOG, FACMG
Professor and Chief
Division of Reproductive Genetics
Department of Obstetrics and Gynecology
Feinberg School of Medicine
Northwestern University
Dr. Shulman is on the advisory board of Bradley Pharmaceuticals, Inc.

Copyright © 2007 by Elsevier Inc.

A supplement to Ob.Gyn. News.
This supplement is based on physician interviews. It is supported by Kenwood Therapeutics, a division of Bradley Pharmaceuticals, Inc.

To view the supplement, click the image above.

Topic Highlights

• Menopause and Hormone Therapy

• The Cardiovascular Paradox

• Current Recommendations for Postmenopausal Hormone Therapy

• Effective Low-Dose Therapy

• Clinical Trial of Transdermal Estrogen

• Other Considerations of Transdermal Hormone Therapy

Faculty/Faculty Disclosures

Donna Shoupe, MD
Professor, Department of Obstetrics and Gynecology
Keck School of Medicine
University of Southern California
Dr. Shoupe is on the advisory board of Bradley Pharmaceuticals, Inc.
Steven R. Goldstein, MD
Professor of Obstetrics and Gynecology
New York University School of Medicine
Dr. Goldstein has disclosed that he is on the advisory boards of Bradley Pharmaceuticals, Inc., Eli Lilly and Company, GlaxoSmithKline, Merck & Co., Inc., Novogyne Pharmaceuticals, Novo Nordisk, and Pfizer Inc.

With Comments From:
Daniel R. Mishell, Jr., MD
Lyle G. McNiele Professor
Department of Obstetrics/Gynecology
Keck School of Medicine
University of Southern California
Dr. Mishell has disclosed that he is a consultant to Barr Pharmaceuticals, Inc., and Bayer Healthcare Pharmaceuticals Inc.
Alfred Moffett Jr., MD, FACOG
Clinical Assistant Professor, Obstetrics and Gynecology
University of South Florida College of Medicine
OB-GYN Associates of Mid-Florida, P.A.
Dr. Moffett is on the advisory board of Bradley Pharmaceuticals, Inc.
Lee P. Shulman, MD, FACOG, FACMG
Professor and Chief
Division of Reproductive Genetics
Department of Obstetrics and Gynecology
Feinberg School of Medicine
Northwestern University
Dr. Shulman is on the advisory board of Bradley Pharmaceuticals, Inc.

Copyright © 2007 by Elsevier Inc.

A supplement to Ob.Gyn. News.
This supplement is based on physician interviews. It is supported by Kenwood Therapeutics, a division of Bradley Pharmaceuticals, Inc.

To view the supplement, click the image above.

Topic Highlights

• Menopause and Hormone Therapy

• The Cardiovascular Paradox

• Current Recommendations for Postmenopausal Hormone Therapy

• Effective Low-Dose Therapy

• Clinical Trial of Transdermal Estrogen

• Other Considerations of Transdermal Hormone Therapy

Faculty/Faculty Disclosures

Donna Shoupe, MD
Professor, Department of Obstetrics and Gynecology
Keck School of Medicine
University of Southern California
Dr. Shoupe is on the advisory board of Bradley Pharmaceuticals, Inc.
Steven R. Goldstein, MD
Professor of Obstetrics and Gynecology
New York University School of Medicine
Dr. Goldstein has disclosed that he is on the advisory boards of Bradley Pharmaceuticals, Inc., Eli Lilly and Company, GlaxoSmithKline, Merck & Co., Inc., Novogyne Pharmaceuticals, Novo Nordisk, and Pfizer Inc.

With Comments From:
Daniel R. Mishell, Jr., MD
Lyle G. McNiele Professor
Department of Obstetrics/Gynecology
Keck School of Medicine
University of Southern California
Dr. Mishell has disclosed that he is a consultant to Barr Pharmaceuticals, Inc., and Bayer Healthcare Pharmaceuticals Inc.
Alfred Moffett Jr., MD, FACOG
Clinical Assistant Professor, Obstetrics and Gynecology
University of South Florida College of Medicine
OB-GYN Associates of Mid-Florida, P.A.
Dr. Moffett is on the advisory board of Bradley Pharmaceuticals, Inc.
Lee P. Shulman, MD, FACOG, FACMG
Professor and Chief
Division of Reproductive Genetics
Department of Obstetrics and Gynecology
Feinberg School of Medicine
Northwestern University
Dr. Shulman is on the advisory board of Bradley Pharmaceuticals, Inc.

Copyright © 2007 by Elsevier Inc.

A supplement to Ob.Gyn. News. This supplement was sponsored by PerkinElmer.

•Topics
•Faculty/Faculty Disclosure

• Introduction
• Screening for Fetal Chromosomal Abnormalities
• UCB Banking
• Conclusions

Faculty/Faculty Disclosure

Joanne Stone, MD
Director, Perinatal Ultrasound
Division Director, Maternal Fetal Medicine
Department of Obstetrics, Gynecology, and Reproductive Medicine
Mt. Sinai School of Medicine
New York, NY
University of California, San Diego
La Jolla, California
Dr. Stone has nothing to disclose.

Copyright © 2009 by Elsevier Inc.

A supplement to Ob.Gyn. News. This supplement was sponsored by PerkinElmer.

•Topics
•Faculty/Faculty Disclosure

• Introduction
• Screening for Fetal Chromosomal Abnormalities
• UCB Banking
• Conclusions

Faculty/Faculty Disclosure

Joanne Stone, MD
Director, Perinatal Ultrasound
Division Director, Maternal Fetal Medicine
Department of Obstetrics, Gynecology, and Reproductive Medicine
Mt. Sinai School of Medicine
New York, NY
University of California, San Diego
La Jolla, California
Dr. Stone has nothing to disclose.

Copyright © 2009 by Elsevier Inc.

A supplement to Ob.Gyn. News. This supplement was sponsored by PerkinElmer.

•Topics
•Faculty/Faculty Disclosure

• Introduction
• Screening for Fetal Chromosomal Abnormalities
• UCB Banking
• Conclusions

Faculty/Faculty Disclosure

Joanne Stone, MD
Director, Perinatal Ultrasound
Division Director, Maternal Fetal Medicine
Department of Obstetrics, Gynecology, and Reproductive Medicine
Mt. Sinai School of Medicine
New York, NY
University of California, San Diego
La Jolla, California
Dr. Stone has nothing to disclose.

Copyright © 2009 by Elsevier Inc.

A supplement to Ob.Gyn. News.
This supplement was supported by CYTYC Corporation.
The articles are based on interviews with the faculty.

•Topic Highlights/Faculty

To view the supplement, click the image above.

Introduction
Mark H. Einstein, MD, MS, Chair
Director, Clinical Research
Division of Gynecologic Oncology
Department of Obstetrics and Gynecology and Women's Health
Montefiore Medical Center
Bronx, N.Y.
Dr Einstein has received clinical grants from GlaxoSmithKline, Merck & Co., Inc., and Tigris Pharmaceuticals, Inc.

Milestones in Cervical Cancer Detection and Prevention: Significance in Clinical Practice
Mark H. Einstein, MD, MS, Chair

Improving HSIL and Glandular Disease Detection: What the Recent Data Show
Richard Lozano, MD
Director of Cytology
Pathology and Cytology Laboratories, Inc.
Lexington, Ky.
Dr Lozano has nothing to disclose.
and
Harold J. Sauer, MD, FACOG
Associate Professor and Acting Chair
Department of Obstetrics and Gynecology and Reproductive Biology
Michigan State University
Lansing
Dr Sauer has nothing to disclose.

Weighing the Costs and Benefits: Technologic Advances in Cervical Cancer Screening
Warner K. Huh, MD, FACOG, FACS
Assistant Professor
Division of Gynecologic Oncology
University of Alabama at Birmingham
Dr Huh has received clinical grants from 3M Pharmaceuticals, Cytyc Corporation, GlaxoSmithKline, MGI PHARMA, Merck, Roche Molecular Systems, and Tigris Pharmaceuticals. He is a consultant to GlaxoSmithKline, MGI PHARMA, Roche Molecular Systems, and mtm laboratories AG.

Efficacy of HPV Screening Versus Liquid-Based Cervical Cytology and Imaging: What the Data Really Show
Michael Karram, MD, FACOG
President and Medical Director
Seven Hills Women's Health Centers
Cincinnati, Ohio
Dr Karram has nothing to disclose.
and
Michael L. Krychman, MD
Associate Clinical Attending
Sexual Medicine Program
Memorial Sloan-Kettering Cancer Center
New York, N.Y.
Dr Krychman is a consultant to Cytyc.

Copyright © 2007 by Elsevier Inc.

A supplement to Ob.Gyn. News.
This supplement was supported by CYTYC Corporation.
The articles are based on interviews with the faculty.

•Topic Highlights/Faculty

To view the supplement, click the image above.

Introduction
Mark H. Einstein, MD, MS, Chair
Director, Clinical Research
Division of Gynecologic Oncology
Department of Obstetrics and Gynecology and Women's Health
Montefiore Medical Center
Bronx, N.Y.
Dr Einstein has received clinical grants from GlaxoSmithKline, Merck & Co., Inc., and Tigris Pharmaceuticals, Inc.

Milestones in Cervical Cancer Detection and Prevention: Significance in Clinical Practice
Mark H. Einstein, MD, MS, Chair

Improving HSIL and Glandular Disease Detection: What the Recent Data Show
Richard Lozano, MD
Director of Cytology
Pathology and Cytology Laboratories, Inc.
Lexington, Ky.
Dr Lozano has nothing to disclose.
and
Harold J. Sauer, MD, FACOG
Associate Professor and Acting Chair
Department of Obstetrics and Gynecology and Reproductive Biology
Michigan State University
Lansing
Dr Sauer has nothing to disclose.

Weighing the Costs and Benefits: Technologic Advances in Cervical Cancer Screening
Warner K. Huh, MD, FACOG, FACS
Assistant Professor
Division of Gynecologic Oncology
University of Alabama at Birmingham
Dr Huh has received clinical grants from 3M Pharmaceuticals, Cytyc Corporation, GlaxoSmithKline, MGI PHARMA, Merck, Roche Molecular Systems, and Tigris Pharmaceuticals. He is a consultant to GlaxoSmithKline, MGI PHARMA, Roche Molecular Systems, and mtm laboratories AG.

Efficacy of HPV Screening Versus Liquid-Based Cervical Cytology and Imaging: What the Data Really Show
Michael Karram, MD, FACOG
President and Medical Director
Seven Hills Women's Health Centers
Cincinnati, Ohio
Dr Karram has nothing to disclose.
and
Michael L. Krychman, MD
Associate Clinical Attending
Sexual Medicine Program
Memorial Sloan-Kettering Cancer Center
New York, N.Y.
Dr Krychman is a consultant to Cytyc.

Copyright © 2007 by Elsevier Inc.

A supplement to Ob.Gyn. News.
This supplement was supported by CYTYC Corporation.
The articles are based on interviews with the faculty.

•Topic Highlights/Faculty

To view the supplement, click the image above.

Introduction
Mark H. Einstein, MD, MS, Chair
Director, Clinical Research
Division of Gynecologic Oncology
Department of Obstetrics and Gynecology and Women's Health
Montefiore Medical Center
Bronx, N.Y.
Dr Einstein has received clinical grants from GlaxoSmithKline, Merck & Co., Inc., and Tigris Pharmaceuticals, Inc.

Milestones in Cervical Cancer Detection and Prevention: Significance in Clinical Practice
Mark H. Einstein, MD, MS, Chair

Improving HSIL and Glandular Disease Detection: What the Recent Data Show
Richard Lozano, MD
Director of Cytology
Pathology and Cytology Laboratories, Inc.
Lexington, Ky.
Dr Lozano has nothing to disclose.
and
Harold J. Sauer, MD, FACOG
Associate Professor and Acting Chair
Department of Obstetrics and Gynecology and Reproductive Biology
Michigan State University
Lansing
Dr Sauer has nothing to disclose.

Weighing the Costs and Benefits: Technologic Advances in Cervical Cancer Screening
Warner K. Huh, MD, FACOG, FACS
Assistant Professor
Division of Gynecologic Oncology
University of Alabama at Birmingham
Dr Huh has received clinical grants from 3M Pharmaceuticals, Cytyc Corporation, GlaxoSmithKline, MGI PHARMA, Merck, Roche Molecular Systems, and Tigris Pharmaceuticals. He is a consultant to GlaxoSmithKline, MGI PHARMA, Roche Molecular Systems, and mtm laboratories AG.

Efficacy of HPV Screening Versus Liquid-Based Cervical Cytology and Imaging: What the Data Really Show
Michael Karram, MD, FACOG
President and Medical Director
Seven Hills Women's Health Centers
Cincinnati, Ohio
Dr Karram has nothing to disclose.
and
Michael L. Krychman, MD
Associate Clinical Attending
Sexual Medicine Program
Memorial Sloan-Kettering Cancer Center
New York, N.Y.
Dr Krychman is a consultant to Cytyc.

Copyright © 2007 by Elsevier Inc.

A supplement to Ob.Gyn. News.
This supplement is supported by Xanodyne Pharmaceuticals, Inc.

•Topic Highlights
•Faculty/Faculty Disclosures

To view the supplement, click the image above.

• Nutritional Gaps for Women in the United States
• Role of Obstetricians and Gynecologists in Women's Health Care

Faculty/Faculty Disclosures

Linda D. Bradley MD
Vice Chair, Obstetrics
Gynecology & Women's Health Institute
Cleveland Clinic
Cleveland, OH
Dr. Bradley is a consultant for Xanodyne Pharmaceuticals, Inc.

Beth Reardon, MS, RD, LDN
Integrative Nutritionist
Duke Integrative Nutrition
Durham, NC
Dr. Reardon has nothing to disclose.

John M. Thorp, Jr., MD
McAllister Distinguished Professor
Department of Obstetrics and Gynecology
University of North Carolina at Chapel Hill
Chapel Hill, NC
Dr. Thorp has nothing to disclose.

Barbara A. Underwood, PhD
Adjunct Professor of Nutrition
Columbia University
Institute of Human Nutrition
New York, NY
Dr. Underwood has nothing to disclose.

Fernando E. Viteri, MD, ScD
Professor (Emeritus)
Department of Nutritional Sciences and Toxicology
University of California
Berkeley, CA
and
Scientist
Children's Hospital
Oakland Research Institute
Oakland, CA
Dr. Viteri has received clinical grant funding from the University of California Institute for Mexico and the United States.

Copyright © 2009 by Elsevier Inc.

A supplement to Ob.Gyn. News.
This supplement is supported by Xanodyne Pharmaceuticals, Inc.

•Topic Highlights
•Faculty/Faculty Disclosures

To view the supplement, click the image above.

• Nutritional Gaps for Women in the United States
• Role of Obstetricians and Gynecologists in Women's Health Care

Faculty/Faculty Disclosures

Linda D. Bradley MD
Vice Chair, Obstetrics
Gynecology & Women's Health Institute
Cleveland Clinic
Cleveland, OH
Dr. Bradley is a consultant for Xanodyne Pharmaceuticals, Inc.

Beth Reardon, MS, RD, LDN
Integrative Nutritionist
Duke Integrative Nutrition
Durham, NC
Dr. Reardon has nothing to disclose.

John M. Thorp, Jr., MD
McAllister Distinguished Professor
Department of Obstetrics and Gynecology
University of North Carolina at Chapel Hill
Chapel Hill, NC
Dr. Thorp has nothing to disclose.

Barbara A. Underwood, PhD
Adjunct Professor of Nutrition
Columbia University
Institute of Human Nutrition
New York, NY
Dr. Underwood has nothing to disclose.

Fernando E. Viteri, MD, ScD
Professor (Emeritus)
Department of Nutritional Sciences and Toxicology
University of California
Berkeley, CA
and
Scientist
Children's Hospital
Oakland Research Institute
Oakland, CA
Dr. Viteri has received clinical grant funding from the University of California Institute for Mexico and the United States.

Copyright © 2009 by Elsevier Inc.

A supplement to Ob.Gyn. News.
This supplement is supported by Xanodyne Pharmaceuticals, Inc.

•Topic Highlights
•Faculty/Faculty Disclosures

To view the supplement, click the image above.

• Nutritional Gaps for Women in the United States
• Role of Obstetricians and Gynecologists in Women's Health Care

Faculty/Faculty Disclosures

Linda D. Bradley MD
Vice Chair, Obstetrics
Gynecology & Women's Health Institute
Cleveland Clinic
Cleveland, OH
Dr. Bradley is a consultant for Xanodyne Pharmaceuticals, Inc.

Beth Reardon, MS, RD, LDN
Integrative Nutritionist
Duke Integrative Nutrition
Durham, NC
Dr. Reardon has nothing to disclose.

John M. Thorp, Jr., MD
McAllister Distinguished Professor
Department of Obstetrics and Gynecology
University of North Carolina at Chapel Hill
Chapel Hill, NC
Dr. Thorp has nothing to disclose.

Barbara A. Underwood, PhD
Adjunct Professor of Nutrition
Columbia University
Institute of Human Nutrition
New York, NY
Dr. Underwood has nothing to disclose.

Fernando E. Viteri, MD, ScD
Professor (Emeritus)
Department of Nutritional Sciences and Toxicology
University of California
Berkeley, CA
and
Scientist
Children's Hospital
Oakland Research Institute
Oakland, CA
Dr. Viteri has received clinical grant funding from the University of California Institute for Mexico and the United States.

Copyright © 2009 by Elsevier Inc.

A supplement to Ob.Gyn. News.
This educational supplement was supported by an educational grant from CYTYC Corporation.
The articles are based on clinical dialogues with the faculty.

•Topic Highlights/Faculty

To view the supplement, click the image above.

Implications of Computer-Assisted Cervical Screening for the Ob.Gyn. Clinician
Co-Chairs:
Randall K. Gibb, MD
Assistant Professor, Division of Gynecologic Oncology
Washington University School of Medicine
St. Louis, Mo.

Thomas J. Herzog, MD
Director, Division of Gynecologic Oncology
Columbia University College of Physicians and Surgeons
New York, N.Y.

Comparison of Manual and Image-Directed Screening of Liquid-Based Cervical Cytology in a Large Metropolitan Cytology Practice
James R. Lingle, MD
Lingle, Gore, and Harding, P.C.
Englewood, Colo.

Fern S. Miller, MSN, CT(ASCP)
Cytology Manager, Cytology Department
Metropolitan Pathologists
Denver, Colo.

Performance of a Computer-Assisted Imaging System in Detecting High-Grade Squamous Intraepithelial Lesions
Bruce R. Dziura, MD
Chief of Pathology
New England Pathology Associates
Mercy Medical Center
Springfield, Mass

Timothy Kelly Fitzpatrick, MD
Attending Physician
Mercy Medical Center
Springfield, Mass.

Evaluation of a Computer-Assisted Imaging System in Diagnosing Uncommon Malignancies
Andrea E. Dawson, MD
Staff Pathologist
Cleveland Clinic Foundation
Cleveland, Ohio

Holly L. Thacker, MD
Director, Women's Health Center
Cleveland Clinic Foundation
Cleveland, Ohio

The faculty report they have nothing to disclose.

Copyright © 2005 by International Medical News Group

A supplement to Ob.Gyn. News.
This educational supplement was supported by an educational grant from CYTYC Corporation.
The articles are based on clinical dialogues with the faculty.

•Topic Highlights/Faculty

To view the supplement, click the image above.

Implications of Computer-Assisted Cervical Screening for the Ob.Gyn. Clinician
Co-Chairs:
Randall K. Gibb, MD
Assistant Professor, Division of Gynecologic Oncology
Washington University School of Medicine
St. Louis, Mo.

Thomas J. Herzog, MD
Director, Division of Gynecologic Oncology
Columbia University College of Physicians and Surgeons
New York, N.Y.

Comparison of Manual and Image-Directed Screening of Liquid-Based Cervical Cytology in a Large Metropolitan Cytology Practice
James R. Lingle, MD
Lingle, Gore, and Harding, P.C.
Englewood, Colo.

Fern S. Miller, MSN, CT(ASCP)
Cytology Manager, Cytology Department
Metropolitan Pathologists
Denver, Colo.

Performance of a Computer-Assisted Imaging System in Detecting High-Grade Squamous Intraepithelial Lesions
Bruce R. Dziura, MD
Chief of Pathology
New England Pathology Associates
Mercy Medical Center
Springfield, Mass

Timothy Kelly Fitzpatrick, MD
Attending Physician
Mercy Medical Center
Springfield, Mass.

Evaluation of a Computer-Assisted Imaging System in Diagnosing Uncommon Malignancies
Andrea E. Dawson, MD
Staff Pathologist
Cleveland Clinic Foundation
Cleveland, Ohio

Holly L. Thacker, MD
Director, Women's Health Center
Cleveland Clinic Foundation
Cleveland, Ohio

The faculty report they have nothing to disclose.

Copyright © 2005 by International Medical News Group

A supplement to Ob.Gyn. News.
This educational supplement was supported by an educational grant from CYTYC Corporation.
The articles are based on clinical dialogues with the faculty.

•Topic Highlights/Faculty

To view the supplement, click the image above.

Implications of Computer-Assisted Cervical Screening for the Ob.Gyn. Clinician
Co-Chairs:
Randall K. Gibb, MD
Assistant Professor, Division of Gynecologic Oncology
Washington University School of Medicine
St. Louis, Mo.

Thomas J. Herzog, MD
Director, Division of Gynecologic Oncology
Columbia University College of Physicians and Surgeons
New York, N.Y.

Comparison of Manual and Image-Directed Screening of Liquid-Based Cervical Cytology in a Large Metropolitan Cytology Practice
James R. Lingle, MD
Lingle, Gore, and Harding, P.C.
Englewood, Colo.

Fern S. Miller, MSN, CT(ASCP)
Cytology Manager, Cytology Department
Metropolitan Pathologists
Denver, Colo.

Performance of a Computer-Assisted Imaging System in Detecting High-Grade Squamous Intraepithelial Lesions
Bruce R. Dziura, MD
Chief of Pathology
New England Pathology Associates
Mercy Medical Center
Springfield, Mass

Timothy Kelly Fitzpatrick, MD
Attending Physician
Mercy Medical Center
Springfield, Mass.

Evaluation of a Computer-Assisted Imaging System in Diagnosing Uncommon Malignancies
Andrea E. Dawson, MD
Staff Pathologist
Cleveland Clinic Foundation
Cleveland, Ohio

Holly L. Thacker, MD
Director, Women's Health Center
Cleveland Clinic Foundation
Cleveland, Ohio

The faculty report they have nothing to disclose.

Copyright © 2005 by International Medical News Group

A supplement to Ob.Gyn. News.
Supported by an educational grant from Gynecare Worldwide, a division of Ethicon, Inc., a Johnson & Johnson Company.
The articles in this supplement are based on clinical dialogues with the faculty.

•Contents
•Faculty/Faculty Disclosure Statement

To view the supplement, click the image above.

Introduction

Consequences of Heavy Menstrual Bleeding

Types, Patterns, and Causes of Abnormal Uterine Bleeding

• Evaluating the Endometrial Cavity

Treatment Options: Entering the Dialogue

• Medical Therapy

• Surgical Interventions

• Endometrial Ablation Procedures

Considering Cases:

• An Overweight Patient

• A Patient Who Prefers to Avoid Hysterectomy

• A Patient With Postsurgical HMB

Helping Patients Choose

Conclusion

Faculty/Faculty Disclosure Statement

Mary Jane Minkin, MD, FACOG, Chair
Clinical Professor
Department of Obstetrics and Gynecology
Yale University School of Medicine
New Haven, Conn.
Developed a Web site for Gynecare; Speaker's Bureau: Berlex, Inc.

Charles E. Miller, MD, FACOG
Clinical Associate Professor
Department of Obstetrics and Gynecology
University of Illinois at Chicago
Clinical Associate
Department of Obstetrics and Gynecology
University of Chicago
Consultant: Gynecare Worldwide.

Malcolm G. Munro, MD, FRCS(c), FACOG
Professor
Department of Obstetrics and Gynecology
The David Geffen School of Medicine at UCLA
Los Angeles
Attending Staff
Department of Obstetrics and Gynecology
Kaiser Permanente Los Angeles Medical Center
Received Funding for Clinical Grants: Kaiser Research Foundation and Karl Storz Endoscopy-America, Inc.M
Consultant: Boston Scientific Corporation, Gynecare, and Karl Storz Endoscopy.

Robert K. Zurawin, MD, FACOG
Associate Professor
Department of Obstetrics and Gynecology
Baylor College of Medicine
Houston
Consultant/Speaker: Gynecare Worldwide.

Copyright © 2004 by International Medical News Group

A supplement to Ob.Gyn. News.
Supported by an educational grant from Gynecare Worldwide, a division of Ethicon, Inc., a Johnson & Johnson Company.
The articles in this supplement are based on clinical dialogues with the faculty.

•Contents
•Faculty/Faculty Disclosure Statement

To view the supplement, click the image above.

Introduction

Consequences of Heavy Menstrual Bleeding

Types, Patterns, and Causes of Abnormal Uterine Bleeding

• Evaluating the Endometrial Cavity

Treatment Options: Entering the Dialogue

• Medical Therapy

• Surgical Interventions

• Endometrial Ablation Procedures

Considering Cases:

• An Overweight Patient

• A Patient Who Prefers to Avoid Hysterectomy

• A Patient With Postsurgical HMB

Helping Patients Choose

Conclusion

Faculty/Faculty Disclosure Statement

Mary Jane Minkin, MD, FACOG, Chair
Clinical Professor
Department of Obstetrics and Gynecology
Yale University School of Medicine
New Haven, Conn.
Developed a Web site for Gynecare; Speaker's Bureau: Berlex, Inc.

Charles E. Miller, MD, FACOG
Clinical Associate Professor
Department of Obstetrics and Gynecology
University of Illinois at Chicago
Clinical Associate
Department of Obstetrics and Gynecology
University of Chicago
Consultant: Gynecare Worldwide.

Malcolm G. Munro, MD, FRCS(c), FACOG
Professor
Department of Obstetrics and Gynecology
The David Geffen School of Medicine at UCLA
Los Angeles
Attending Staff
Department of Obstetrics and Gynecology
Kaiser Permanente Los Angeles Medical Center
Received Funding for Clinical Grants: Kaiser Research Foundation and Karl Storz Endoscopy-America, Inc.M
Consultant: Boston Scientific Corporation, Gynecare, and Karl Storz Endoscopy.

Robert K. Zurawin, MD, FACOG
Associate Professor
Department of Obstetrics and Gynecology
Baylor College of Medicine
Houston
Consultant/Speaker: Gynecare Worldwide.

Copyright © 2004 by International Medical News Group

A supplement to Ob.Gyn. News.
Supported by an educational grant from Gynecare Worldwide, a division of Ethicon, Inc., a Johnson & Johnson Company.
The articles in this supplement are based on clinical dialogues with the faculty.

•Contents
•Faculty/Faculty Disclosure Statement

To view the supplement, click the image above.

Introduction

Consequences of Heavy Menstrual Bleeding

Types, Patterns, and Causes of Abnormal Uterine Bleeding

• Evaluating the Endometrial Cavity

Treatment Options: Entering the Dialogue

• Medical Therapy

• Surgical Interventions

• Endometrial Ablation Procedures

Considering Cases:

• An Overweight Patient

• A Patient Who Prefers to Avoid Hysterectomy

• A Patient With Postsurgical HMB

Helping Patients Choose

Conclusion

Faculty/Faculty Disclosure Statement

Mary Jane Minkin, MD, FACOG, Chair
Clinical Professor
Department of Obstetrics and Gynecology
Yale University School of Medicine
New Haven, Conn.
Developed a Web site for Gynecare; Speaker's Bureau: Berlex, Inc.

Charles E. Miller, MD, FACOG
Clinical Associate Professor
Department of Obstetrics and Gynecology
University of Illinois at Chicago
Clinical Associate
Department of Obstetrics and Gynecology
University of Chicago
Consultant: Gynecare Worldwide.

Malcolm G. Munro, MD, FRCS(c), FACOG
Professor
Department of Obstetrics and Gynecology
The David Geffen School of Medicine at UCLA
Los Angeles
Attending Staff
Department of Obstetrics and Gynecology
Kaiser Permanente Los Angeles Medical Center
Received Funding for Clinical Grants: Kaiser Research Foundation and Karl Storz Endoscopy-America, Inc.M
Consultant: Boston Scientific Corporation, Gynecare, and Karl Storz Endoscopy.

Robert K. Zurawin, MD, FACOG
Associate Professor
Department of Obstetrics and Gynecology
Baylor College of Medicine
Houston
Consultant/Speaker: Gynecare Worldwide.

Copyright © 2004 by International Medical News Group

A supplement to Ob. Gyn. News.
Supported by a restricted educational grant from 3M Pharmaceuticals.
Highlights of presentations that took place at a continuing medical education conference held April 5-6, 2003, Washington, DC.

•Contents/Faculty Disclosure

To view the supplement, click the image above.

Introduction
Jack D. Sobel, MD
Professor, Chief
Division of Infectious Disease
Wayne State University School of Medicine
Harper Hospital
Detroit, MI
Clinical Grants: 3M Pharmaceuticals, Pfizer, and Ortho-McNeil. Discusses the investigational use of fluconazole and 17.4% topical flucytosine cream for treating Candida glabrata, and 10% hydrocortisone for treating erosive lichen planus.

Phillip G. Stubblefield, MD
Professor and Chairman, Obstetrics and Gynecology
Boston University School of Medicine
Director, Obstetrics and Gynecology
Boston Medical Center
Boston, MA
Nothing to disclose.

Jonathan M. Zenilman, MD
Professor, Infectious Diseases Division
Johns Hopkins School of Medicine
Baltimore, MD
Clinical Grants/Research: Osmetech PLC; Consultant: Merck and Company; Speaker's Bureau: GlaxoSmithKline, Pfizer, Inc.

Normal Vaginal Flora
Jeanne M. Marrazzo, MD, MPH
Assistant Professor, Department of Medicine
Division of Allergy and Infectious Diseases
University of Washington, Harborview Medical Center
Seattle, WA
Discusses the use of intravaginal Lactobacillus crispatus capsules for the treatment of bacterial vaginosis.

Diagnosis and Treatment of Routine and Resistant Trichomoniasis
Anne M. Rompalo, MD, ScM
Associate Professor, Infectious Diseases Division
Johns Hopkins School of Medicine
Baltimore, MD
Clinical Grants/Research: GlaxoSmithKline; Speaker's Bureau: GlaxoSmithKline, Pfizer, Inc.

New Findings in Routine and Recurrent Vulvovaginal Candidiasis Treatment
Jack D. Sobel, MD

Overview of Bacterial Vaginosis and Its Role in Upper Genital Tract Infection
David A. Eschenbach, MD
Professor and Director, Women's Health
Chair, Department of Obstetrics and Gynecology
University of Washington
Seattle, WA
Consultant: 3M Pharmaceuticals.

Noninfectious Vulvovaginal Symptoms as Manifestations of Systemic Diseases
Jack D. Sobel, MD

Copyright © 2003 by International Medical News Group

A supplement to Ob. Gyn. News.
Supported by a restricted educational grant from 3M Pharmaceuticals.
Highlights of presentations that took place at a continuing medical education conference held April 5-6, 2003, Washington, DC.

•Contents/Faculty Disclosure

To view the supplement, click the image above.

Introduction
Jack D. Sobel, MD
Professor, Chief
Division of Infectious Disease
Wayne State University School of Medicine
Harper Hospital
Detroit, MI
Clinical Grants: 3M Pharmaceuticals, Pfizer, and Ortho-McNeil. Discusses the investigational use of fluconazole and 17.4% topical flucytosine cream for treating Candida glabrata, and 10% hydrocortisone for treating erosive lichen planus.

Phillip G. Stubblefield, MD
Professor and Chairman, Obstetrics and Gynecology
Boston University School of Medicine
Director, Obstetrics and Gynecology
Boston Medical Center
Boston, MA
Nothing to disclose.

Jonathan M. Zenilman, MD
Professor, Infectious Diseases Division
Johns Hopkins School of Medicine
Baltimore, MD
Clinical Grants/Research: Osmetech PLC; Consultant: Merck and Company; Speaker's Bureau: GlaxoSmithKline, Pfizer, Inc.

Normal Vaginal Flora
Jeanne M. Marrazzo, MD, MPH
Assistant Professor, Department of Medicine
Division of Allergy and Infectious Diseases
University of Washington, Harborview Medical Center
Seattle, WA
Discusses the use of intravaginal Lactobacillus crispatus capsules for the treatment of bacterial vaginosis.

Diagnosis and Treatment of Routine and Resistant Trichomoniasis
Anne M. Rompalo, MD, ScM
Associate Professor, Infectious Diseases Division
Johns Hopkins School of Medicine
Baltimore, MD
Clinical Grants/Research: GlaxoSmithKline; Speaker's Bureau: GlaxoSmithKline, Pfizer, Inc.

New Findings in Routine and Recurrent Vulvovaginal Candidiasis Treatment
Jack D. Sobel, MD

Overview of Bacterial Vaginosis and Its Role in Upper Genital Tract Infection
David A. Eschenbach, MD
Professor and Director, Women's Health
Chair, Department of Obstetrics and Gynecology
University of Washington
Seattle, WA
Consultant: 3M Pharmaceuticals.

Noninfectious Vulvovaginal Symptoms as Manifestations of Systemic Diseases
Jack D. Sobel, MD

Copyright © 2003 by International Medical News Group

A supplement to Ob. Gyn. News.
Supported by a restricted educational grant from 3M Pharmaceuticals.
Highlights of presentations that took place at a continuing medical education conference held April 5-6, 2003, Washington, DC.

•Contents/Faculty Disclosure

To view the supplement, click the image above.

Introduction
Jack D. Sobel, MD
Professor, Chief
Division of Infectious Disease
Wayne State University School of Medicine
Harper Hospital
Detroit, MI
Clinical Grants: 3M Pharmaceuticals, Pfizer, and Ortho-McNeil. Discusses the investigational use of fluconazole and 17.4% topical flucytosine cream for treating Candida glabrata, and 10% hydrocortisone for treating erosive lichen planus.

Phillip G. Stubblefield, MD
Professor and Chairman, Obstetrics and Gynecology
Boston University School of Medicine
Director, Obstetrics and Gynecology
Boston Medical Center
Boston, MA
Nothing to disclose.

Jonathan M. Zenilman, MD
Professor, Infectious Diseases Division
Johns Hopkins School of Medicine
Baltimore, MD
Clinical Grants/Research: Osmetech PLC; Consultant: Merck and Company; Speaker's Bureau: GlaxoSmithKline, Pfizer, Inc.

Normal Vaginal Flora
Jeanne M. Marrazzo, MD, MPH
Assistant Professor, Department of Medicine
Division of Allergy and Infectious Diseases
University of Washington, Harborview Medical Center
Seattle, WA
Discusses the use of intravaginal Lactobacillus crispatus capsules for the treatment of bacterial vaginosis.

Diagnosis and Treatment of Routine and Resistant Trichomoniasis
Anne M. Rompalo, MD, ScM
Associate Professor, Infectious Diseases Division
Johns Hopkins School of Medicine
Baltimore, MD
Clinical Grants/Research: GlaxoSmithKline; Speaker's Bureau: GlaxoSmithKline, Pfizer, Inc.

New Findings in Routine and Recurrent Vulvovaginal Candidiasis Treatment
Jack D. Sobel, MD

Overview of Bacterial Vaginosis and Its Role in Upper Genital Tract Infection
David A. Eschenbach, MD
Professor and Director, Women's Health
Chair, Department of Obstetrics and Gynecology
University of Washington
Seattle, WA
Consultant: 3M Pharmaceuticals.

Noninfectious Vulvovaginal Symptoms as Manifestations of Systemic Diseases
Jack D. Sobel, MD

Copyright © 2003 by International Medical News Group